- Home
- HRMY vs ZGN Comparison
HRMY vs ZGN Comparison
Compare HRMY & ZGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- ZGN
- Stock Information
- Founded
- HRMY 2017
- ZGN 1910
- Country
- HRMY United States
- ZGN Italy
- Employees
- HRMY N/A
- ZGN N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- ZGN Apparel
- Sector
- HRMY Health Care
- ZGN Consumer Discretionary
- Exchange
- HRMY Nasdaq
- ZGN Nasdaq
- Market Cap
- HRMY 2.0B
- ZGN 2.0B
- IPO Year
- HRMY 2020
- ZGN N/A
- Fundamental
- Price
- HRMY $32.16
- ZGN $9.15
- Analyst Decision
- HRMY Strong Buy
- ZGN Buy
- Analyst Count
- HRMY 9
- ZGN 2
- Target Price
- HRMY $54.22
- ZGN $8.05
- AVG Volume (30 Days)
- HRMY 620.8K
- ZGN 1.9M
- Earning Date
- HRMY 08-05-2025
- ZGN 03-27-2025
- Dividend Yield
- HRMY N/A
- ZGN 1.54%
- EPS Growth
- HRMY 13.13
- ZGN N/A
- EPS
- HRMY 2.62
- ZGN 0.31
- Revenue
- HRMY $744,852,000.00
- ZGN $2,015,371,157.00
- Revenue This Year
- HRMY $20.10
- ZGN $0.74
- Revenue Next Year
- HRMY $18.01
- ZGN $4.74
- P/E Ratio
- HRMY $12.27
- ZGN $29.46
- Revenue Growth
- HRMY 20.62
- ZGN 2.21
- 52 Week Low
- HRMY $26.47
- ZGN $6.05
- 52 Week High
- HRMY $41.61
- ZGN $11.69
- Technical
- Relative Strength Index (RSI)
- HRMY 43.25
- ZGN 63.83
- Support Level
- HRMY $31.70
- ZGN $8.24
- Resistance Level
- HRMY $33.69
- ZGN $8.99
- Average True Range (ATR)
- HRMY 0.89
- ZGN 0.32
- MACD
- HRMY -0.10
- ZGN -0.01
- Stochastic Oscillator
- HRMY 37.30
- ZGN 86.32
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.